Clinical Trials · NCT07855133
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
- Phase
- Phase 1
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 60
- Start date
- Sep 2026
- Locations
- 2 sites, United States
- Primary endpoint
- Number of treatment emergent adverse events (TEAE)